What it sells
Full Stack Pharmaceutical Company for Personalized Peptides and GLP-1s
Business model breakdown
Buyer: who owns the budget?
UnverifiedPatients pay directly (no insurance required); prescribing doctors and clinics are the partner/channel.
Trigger: what makes them buy now?
UnverifiedConsumers want GLP-1/peptide therapy (e.g. tirzepatide) online at a lower cash price without insurance.
Workflow: what inputs become what output?
Patient completes online intake, a licensed doctor sets the dose and prescribes, a partnered pharmacy compounds and validates the medication, and it ships directly to the patient with free two-day shipping; refills are paced with the doctor.
Economics: what it saves and how it charges
Monthly cash-pay subscriptions per medication (e.g. tirzepatide shown as $78/month, struck from $195); also sells platform access to doctors and clinics so they can run personalized-medicine programs without building pharmacy infrastructure.
Distribution: how it reaches customers
Direct-to-consumer online funnel with an AI text assistant, plus a "Request partnership call" channel for doctors and clinics.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2026 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.